Advanced Search

Share Coverage



Category: Chemicals and Pharmaceuticals / Consumer Protection / Courts and Trials

Nurofen facing $6m headache for misleading consumers

Tuesday, 12 Apr 2016 12:53:25 | Nick Dole

Nurofen's specific-pain product range was found to be misleading. (accc.gov.au)

The makers of Nurofen should be fined $6 million for misleading conduct, the Australian Competition and Consumer Commission (ACCC) has told the Federal Court.

The consumer watchdog has already won its case against Reckitt Benckiser for a range of "pain specific" products, which all contained the same ingredient and did the same thing.

The products promised to relieve either back pain, period pain, tension headache or migraine, even though it is not possible to target pain relief in such a manner.

All of the products contained the exact same active ingredient: ibuprofen lysine 342mg.

The barrister for the ACCC, Katrina Banks-Smith SC, said Reckitt Benckiser made "substantial profits" from its misleading marketing and a large fine was warranted.

"There needs to be some serious taking away of profit," she said.

Ms Banks-Smith SC told the court that consumers had been financially harmed over the space of five years as the pain-specific products were sold at almost double the price of Nurofen's standard range.

"They purchased a product they thought was special and it wasn't. They were misled," she said.

Painkillers able to target pain? No way

Claims that suggest you need a different painkiller for back pain, migraine, period pain or tension headache are simply untrue, health and consumer experts say.

The ACCC also argued Nurofen's competitors were disadvantaged as there was less shelf space available.

In December, the company was given three months to withdraw the products from sale.

In the interim, it agreed to place stickers on the products to correct the misleading claims made on the packaging.

However, lawyers for the ACCC said those stickers were being obscured in some supermarkets.

Ms Banks-Smith said it was proved the company lacked a "culture of compliance" and asked the court to consider that in its penalty decision.

During the hearing, Justice James Edelman joked the weight of evidence may induce a headache in anyone reading it.

"I can suggest some pain relief products your Honour," the ACCC's barrister replied.

Lawyers for Reckitt Benckiser will respond this afternoon.

ABC TV's The Checkout program highlighted the marketing tactic in 2013, and Nurofen was awarded a Shonky Award for the practice by consumer group Choice in 2010.

AustraliaPlus


 

Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.

沪公网安备 31010602000204号

Email this to your friend